Beyond Air shares plunge 16.09% intraday after Q2 revenue misses estimates, wider losses, and supply chain delays for second-gen LungFit PH.

Beyond Air (XAIR) fell 16.09% intraday following its Q2 2026 earnings report, which revealed revenue of $1.8 million—128% higher year-over-year but below the $2.54 million estimate—and a wider-than-expected net loss of $1.25 per share. The decline was driven by operational challenges, including supply chain delays for its second-generation LungFit PH system, flat sequential revenue growth, and a $0.3 million gross loss. Management attributed the shortfall to hospital purchasing cycle variability and leadership transition risks, while revised $8–$10 million annual revenue guidance underscored investor skepticism about scaling profitability. Despite international expansion and cost reductions, the revenue and EPS misses, coupled with debt financing costs, overshadowed long-term growth prospects, triggering the sharp intraday sell-off.